Telix Pharmaceuticals Limited (ASX:TLX)

Market Cap	5.80B
Revenue (ttm)	783.21M
Net Income (ttm)	49.92M
Shares Out	338.38M
EPS (ttm)	0.14
PE Ratio	118.46
Forward PE	59.29
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,709,794
Average Volume	2,936,116
Open	17.26
Previous Close	17.13
Day's Range	16.82 - 17.47
52-Week Range	16.00 - 31.97
Beta	2.43
RSI	24.98
Earnings Date	Aug 19, 2025

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 234
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: TLX

Financial Performance

In 2024, Telix Pharmaceuticals's revenue was 783.21 million, an increase of 55.85% compared to the previous year's 502.55 million. Earnings were 49.92 million, an increase of 857.95%.